SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 71 of 85
Word Count: 1459
Character Count: 8815

Document Content:

have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any securities to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the Representative has been obtained to each such proposed offer or resale. For the purposes of this provision, the expression an “offer to the public” in relation to securities in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129. Hong Kong

The
securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional
investors” as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and
any rules made thereunder; or (b) in other circumstances which do not result in the document being a “prospectus” as defined
in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong), or the CO, or which do not constitute an
offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the securities has been or may
be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is
directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under
the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside
Hong Kong or only to “professional investors” as defined in the SFO and any rules made thereunder.

Israel

This
prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, and has not been filed with or approved by the
Israel Securities Authority. In Israel, this prospectus may be distributed only to, and is directed only at, investors listed in the
first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds; provident funds;
insurance companies; banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange Ltd., underwriters, each
purchasing for their own account; venture capital funds; entities with equity in excess of NIS 50 million and “qualified individuals,”
each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors. Qualified
investors shall be required to submit written confirmation that they fall within the scope of the Addendum.

Japan

The
securities have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act.
Accordingly, none of the securities nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the
benefit of, any “resident” of Japan (which term as used herein means any person resident in Japan, including any corporation
or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or
for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance
with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect
at the relevant time.

Singapore

This
prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the underwriters have not offered
or sold any securities or caused the securities to be made the subject of an invitation for subscription or purchase and will not offer
or sell any securities or cause the securities to be made the subject of an invitation for subscription or purchase, and has not circulated
or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or
sale, or invitation for subscription or purchase, of the securities, whether directly or indirectly, to any person in Singapore other
than:

an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter
289) of Singapore, as modified or amended from time to time, or the SFA) pursuant to Section
274 of the SFA;

a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of
the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the
conditions specified in Section 275 of the SFA; or

(c)	otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of
the SFA.

Where
the securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the
sole business of which is to hold investments and the entire share capital of which is owned
by one or more individuals, each of whom is an accredited investor; or

trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments
and each beneficiary of the trust is an individual who is an accredited investor, securities
or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA)
of that corporation or the beneficiaries’ rights and interest (howsoever described)
in that trust shall not be transferred within six months after that corporation or that trust
has acquired the securities pursuant to an offer made under Section 275 of the SFA except:

an institutional investor or to a relevant person, or to any person arising from an offer
referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;

ii.	where
no consideration is or will be given for the transfer;

iii.	where
the transfer is by operation of law;

specified in Section 276(7) of the SFA; or

specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities
and Securities-based Derivatives Contracts) Regulations 2018.

Switzerland

The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock
exchange or regulated trading facility in Switzerland. This prospectus does not constitute a prospectus within the meaning of, and has
been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any
other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material
relating to the securities or this offering may be publicly distributed or otherwise made publicly available in Switzerland.

Neither
this prospectus nor any other offering or marketing material relating to this offering, the Company, the securities have been or will
be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of
securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of securities has
not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded
to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities.

United
Kingdom

The
securities may not be made in the United Kingdom, except that an offer to the public of any securities may be made in the United Kingdom
at any time:

any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus
Regulation;

fewer than 150 natural or legal persons (other than qualified investors as defined under
Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the
Representative for any such offer; or

any other circumstances falling within Section 86 of the Financial Services and Markets Act
2000 (as amended, the “FSMA”);

provided
that no such offer of securities shall result in the requirement for the publication by us of a prospectus pursuant to Section 85
of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.